Summary
Gilead Sciences, Inc.'s 2019 10-K filing highlights a year of solid financial performance, driven by continued growth in its HIV franchise, which accounted for approximately 74% of total product sales. Total revenues reached $22.4 billion, a slight increase from the prior year, primarily due to higher HIV product sales, notably Biktarvy, and increased use of Descovy for PrEP. The company also saw significant growth in its cell therapy business, Yescarta. However, sales for Hepatitis C (HCV) products declined due to lower pricing and patient starts, and older HIV products like Truvada saw decreased sales as patients shifted to newer TAF-based regimens and with the anticipation of generic competition. Gilead is actively positioning itself for future growth, aiming to launch 10 new transformative therapies by 2030. Key strategic moves in 2019 included a significant R&D collaboration with Galapagos NV, aimed at accelerating the development of treatments for inflammatory and fibrotic diseases, and progress in its oncology pipeline with Kite Pharma. The company's financial position remains strong, with substantial cash reserves, although R&D expenses increased significantly due to the Galapagos collaboration. Investors should monitor the company's ongoing pipeline development, particularly in inflammatory diseases and oncology, and remain aware of the potential impact of litigation, competition, and evolving healthcare regulations on future performance.
Financial Highlights
57 data points| Revenue | $22.45B |
| Cost of Revenue | $4.67B |
| Gross Profit | $17.77B |
| R&D Expenses | $9.11B |
| SG&A Expenses | $4.38B |
| Operating Expenses | $18.16B |
| Operating Income | $4.29B |
| Interest Expense | $995.00M |
| Net Income | $5.39B |
| EPS (Basic) | $4.24 |
| EPS (Diluted) | $4.22 |
| Shares Outstanding (Basic) | 1.27B |
| Shares Outstanding (Diluted) | 1.28B |
Key Highlights
- 1HIV franchise sales grew 12% to $16.4 billion in 2019, driven by strong demand for Biktarvy and increased use of Descovy for PrEP.
- 2Total revenues increased 1% to $22.4 billion in 2019, with product sales reaching $22.1 billion.
- 3HCV product sales decreased by 20% to $2.9 billion due to lower pricing and patient starts.
- 4Yescarta, a cell therapy, saw a significant 73% increase in sales, reaching $456 million.
- 5R&D expenses more than doubled to $9.1 billion, largely due to a $3.9 billion upfront payment for the Galapagos collaboration.
- 6Gilead entered into a transformative R&D collaboration with Galapagos NV to develop novel treatments for inflammatory and fibrotic diseases.
- 7The company faces significant litigation risks, notably patent infringement lawsuits concerning Yescarta and Biktarvy, which could lead to substantial damages.
- 8Gilead has a robust cash position ($25.8 billion at year-end 2019) and continues to return capital to shareholders through dividends and share repurchases.